Public Employees Retirement Association of Colorado Increases Holdings in ResMed Inc. (RMD)

Public Employees Retirement Association of Colorado raised its position in shares of ResMed Inc. (NYSE:RMD) by 3.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,251 shares of the medical equipment provider’s stock after buying an additional 889 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in ResMed were worth $2,308,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RMD. Dimensional Fund Advisors LP raised its stake in ResMed by 0.7% during the second quarter. Dimensional Fund Advisors LP now owns 379,317 shares of the medical equipment provider’s stock valued at $29,535,000 after buying an additional 2,530 shares in the last quarter. Stifel Financial Corp raised its position in shares of ResMed by 55.4% during the 2nd quarter. Stifel Financial Corp now owns 9,033 shares of the medical equipment provider’s stock worth $703,000 after purchasing an additional 3,219 shares during the period. Janus Henderson Group PLC raised its position in shares of ResMed by 1,205.7% during the 2nd quarter. Janus Henderson Group PLC now owns 222,648 shares of the medical equipment provider’s stock worth $17,337,000 after purchasing an additional 205,596 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of ResMed by 1.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 209,022 shares of the medical equipment provider’s stock worth $16,277,000 after purchasing an additional 3,728 shares during the period. Finally, Toronto Dominion Bank raised its position in shares of ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the period. Hedge funds and other institutional investors own 61.47% of the company’s stock.

In related news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $85.36, for a total value of $106,700.00. Following the completion of the transaction, the chief financial officer now directly owns 79,572 shares of the company’s stock, valued at approximately $6,792,265.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Pendarvis sold 2,810 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $96.03, for a total value of $269,844.30. Following the completion of the transaction, the insider now directly owns 97,263 shares of the company’s stock, valued at $9,340,165.89. The disclosure for this sale can be found here. Insiders sold a total of 49,802 shares of company stock valued at $4,824,727 over the last three months. Corporate insiders own 1.77% of the company’s stock.

A number of analysts have recently weighed in on RMD shares. Zacks Investment Research cut ResMed from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Northland Securities reiterated a “sell” rating and set a $55.00 price target on shares of ResMed in a research report on Friday, October 27th. BMO Capital Markets increased their price target on ResMed to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, January 23rd. Macquarie cut ResMed from a “neutral” rating to a “sell” rating in a research report on Tuesday, January 23rd. Finally, Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $76.00.

ResMed Inc. (NYSE:RMD) opened at $93.47 on Thursday. ResMed Inc. has a fifty-two week low of $67.04 and a fifty-two week high of $104.78. The stock has a market capitalization of $13,260.00, a P/E ratio of 32.57 and a beta of 0.92.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The business had revenue of $601.27 million during the quarter, compared to analyst estimates of $583.77 million. During the same period in the prior year, the company posted $0.73 EPS. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. sell-side analysts anticipate that ResMed Inc. will post 3.34 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be issued a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 1.50%. The ex-dividend date is Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is 48.78%.

COPYRIGHT VIOLATION NOTICE: “Public Employees Retirement Association of Colorado Increases Holdings in ResMed Inc. (RMD)” was first reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://weekherald.com/2018/02/15/public-employees-retirement-association-of-colorado-increases-holdings-in-resmed-inc-rmd.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply